Trials / Completed
CompletedNCT00115414
Same Day Dosing of Pegfilgrastim in Breast Cancer Patients Undergoing Chemotherapy (TAC)
A Randomized, Double-Blind, Phase 2 Study Evaluating the Safety of Same Day Versus Next Day Administration of Pegfilgrastim With Docetaxel, Doxorubicin, and Cyclophosphamide (TAC) in Women With Breast Cancer
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- —
- Sponsor
- Amgen · Industry
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to provide data on the safety and efficacy of pegfilgrastim when administered on the same day versus the next day of chemotherapy, as measured by the duration of grade 4 neutropenia.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | pegfilgrastim | |
| DRUG | docetaxel | |
| DRUG | doxorubicin | |
| DRUG | cyclophosphamide |
Timeline
- First posted
- 2005-06-23
- Last updated
- 2008-08-01
Source: ClinicalTrials.gov record NCT00115414. Inclusion in this directory is not an endorsement.